Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Delivra Health BrandsFRA:3F0 +101.52%27 Equity-to-Asset is 0.41 as of Mar. 2026, which is 20% below its 10-year median of 0.51. GuruFocus rates FRA:3F0 with a GF Score™ of 27/100 and a GF Value™ of €0.14 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Delivra Health Brands ranks worse than 73.78% on this metric.
Delivra Health Brands (FRA:3F0) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Delivra Health Brands Equity-to-Asset Related Terms
Delivra Health Brands Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Delivra Health Brands's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Delivra Health Brands's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delivra Health Brands Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Delivra Health Brands's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Delivra Health Brands's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Delivra Health Brands's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delivra Health Brands (FRA:3F0) has a Equity-to-Asset of 0.41 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Delivra Health Brands and its competitors. This is 20% below median its historical median of 0.51. According to the industry distribution chart, Delivra Health Brands ranks #743 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 73.8%.
Is Delivra Health Brands' Equity-to-Asset too high?
Delivra Health Brands' current Equity-to-Asset of 0.41 is 20% below median its 10-year median of 0.51. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Delivra Health Brands' value of 0.41 is 31.7% below this industry median. Based on the distribution chart, Delivra Health Brands ranks #743 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Delivra Health Brands has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Delivra Health Brands' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Delivra Health Brands ranks #743 out of 1007 companies for Equity-to-Asset. This places Delivra Health Brands in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Delivra Health Brands' value of 0.41 is 31.7% below this benchmark. While the company's 10-year median is 0.51 vs. the industry median of 0.60, Delivra Health Brands has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delivra Health Brands's current Equity-to-Asset of 0.41 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Delivra Health Brands and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delivra Health Brands's current Equity-to-Asset is 0.41, which is 20% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delivra Health Brands stock overvalued right now?
Based on GuruFocus' analysis, Delivra Health Brands (FRA:3F0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.07 — trading 52.5% below its estimated fair value. The current Equity-to-Asset is 0.41, which is 20% below median its 10-year median of 0.51 and 31.7% below the Drug Manufacturers industry median of 0.60. Delivra Health Brands' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Delivra Health Brands (FRA:3F0), the current Equity-to-Asset is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delivra Health Brands (FRA:3F0) Overvalued in 2026?
Based on GuruFocus' analysis, Delivra Health Brands stock appears to be undervalued.
The current stock price of €0.07 is trading 52.5% below its estimated GF Value™ of €0.14.
GuruFocus considers Delivra Health Brands to be Possible Value Trap.
Key valuation signals for FRA:3F0:
Equity-to-Asset: 0.41 (20% below median its 10-year median of 0.51)
GF Value™: €0.14 vs. price of €0.07 (52.5% below fair value)
Industry Position: 31.7% below the Drug Manufacturers median (#743 of 1007)
No single metric tells the full story. See the FRA:3F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delivra Health Brands Inc helping people take control of health with alternative wellness solutions. Its portfolio features brands like Dream Water and LivRelief that deliver relief from common, everyday issues like chronic pain, anxiety, and sleeplessness. The principal activities of the company are to provide lifestyle and health and wellness products to consumers and patients in regulated markets. The company geographically operates in Canada and United States, out of which it generates maximum revenue from Unites States.
27GF Score
Get the complete analysis for FRA:3F0
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3F0 has been successfully added to your 
